Clinical reports on cancer

Intractable duodenal ulcer

Female in the 80s
Chief Complaint: Abdominal pain
Medical History: intractable duodenal ulcer, rheumatoid arthritis and angina pectoris

Current Medical history:
She received helicobacter pylori eradication and PPI therapy, to combat the duodenal ulcer in May 2002 which then improved. Then, in August the same year, it relapsed. Again, she received H. pylori eradication treatment and PPI therapy. However, there were no signs of improvement this time. This was the time when we proposed the administration of Fucoidan Mix AG. After providing sufficient information on fucoidan, she and her family members agreed and she began receiving Fucoidan Mix AG treatment. Her condition improved dramatically enough to be discharged from hospital. Thereafter, we continued prescribing Fucoidan Mix AG and PPI. She visited our hospital complaining of abdominal pain in June 2003. The examination result showed that the duodenal ulcer had relapsed. After interviewing the patient, it was found that she had made her own judgement and discontinued taking Fucoidan Mix AG since April 2003. She had continued only the PPI. So, we started the administration of Fucoidan Mix AG again.

Treatment outcomes:
When her duodenal ulcer was found to have relapsed, she was provided with Fucoidan Mix AG. In one week, the ulcer improved.

※Data taken over the period of treatment

《Endoscope of the duodenal ulcer area》
Fucoidan Mix AG intake per day: Approximately 2.5g

June 2003 Recurrence of Duodenal ulcer
June 2003, one week after the discovery of duodenal ulcer recurrence

Fucoidan Mix AG・・・It is composed of mozuku extracted fucoidan, mekabu extracted fucoidan and agaricus mycelium.

Today, active research is conducted on fucoidan and various bioactive functions of fucoidan, such as “anti-cancer action,” “cholesterol-lowering action,” “blood-pressure lowering action” and “anti-virus action,” have been revealed.

Back to Top